Join Us for a Special Webinar Featuring the New TK 210 ELISA Assay Kit

Wednesday, November 15, 2017 at 10:00 AM EST



AroCell TK 210 ELISA:

A Novel Proliferation Biomarker to 

Study Hematological Malignancies

Thymidine Kinase 1 (TK1) has been long known as a valuable biomarker of cellular proliferation. However, previous methods have been based on enzyme activity measurements that are complex and require specialized equipment. Introducing the AroCell TK 210 ELISA as a new valuable assay for TK1 that brings the simplicity and robustness in a widely available assay kit (sold only in the US by Eagle Biosciences). Based on unique monoclonal antibodies (TK 210 epitope), the AroCell TK 210 ELISA Assay Kit creates an easy to use assay and provides new opportunities for studying cellular proliferation, tumor cell turnover and therapy response in subjects with hematological malignancies. 

During this webinar, you will learn the importance of proliferation biomarkers, and their key role in monitoring malignancies, as well as the aiding in making prognoses which could provide early insights into the effects of therapy. Since Thymidine kinase 1 (TK1) is a well-known proliferation biomarker, studying this biomarker has been based on enzyme activity methods and may underestimate serum TK1 levels, particularly in subjects with solid tumors. Improved immunoassays of TK1 based on the TK 210 antigen (AroCell TK 210 ELISA) has shown promising insight of studying these hematological malignancies. 


Meet the Speakers: 

Staffan Eriksson | Professor in Medical and Physilogical Chemistry at the

Swedish University of Agricultural Sciences

Steffan Eriksson has been active in the research of medical biochemistry and Thymidine Kinase for many decades, and has published over 120 scientific studies related to these topics. He is also founder of AroCell AB and one of the inventors of the TK 210 ELISA Assay test for measuring cell grown and turnover. 


Martin Shaw | AroCell Development Manager

Martin Shaw has had a long experience in the development and application of many novel biomarkers. He has participated in industry-wide consortia on the qualification of biomarkers for application in pre-clinical and clinical trials. He has spoken at many congresses including being a guest speaker at the FDA. 


We Hope You Can Join Us!



If you would like to receive a white paper on the use of TK1 and TK 210
ELISA in studying hematological malignancies, please 
click here

AroCell signs distribution agreement with Eagle Biosciences in the United States



AroCell AB (publ) announced today that a distribution
agreement has been signed with the New England-based company Eagle
Biosciences, for distribution of the AroCell TK 210 ELISA test in North

The TK 210 ELISA test measures TK1 protein levels for valuable
information about the speed of cell turnover. As tumors have high cell
turnover, the test may provide valuable information for prognosis and
optimization of treatment strategy.

“We are delighted to partner with Eagle Biosciences for the
distribution of the TK 210 ELISA test”, states Jan Stålemark, AroCell
CEO. “Eagle Biosciences is a leading provider of ELISA assay kits in
North America, and has primary focus on providing innovative products
that aid medical research and clinical laboratories. This highly concurs
with our strategy to make the TK 210 ELISA test widely available for
investigational use in the US, in order to facilitate use of the product
in cancer research institutions as well as within the pharmaceutical

The TK 210 ELISA test will be commercially available immediately
through Eagle Biosciences for investigational use only in the United
States.  The product can be found on the Eagle Biosciences website through the following link:



About AroCell

AroCell AB (AROC) is a Swedish company that develops
standardized modern blood tests to support the prognosis and follow up
of cancer patients. AroCell’s new technology is based on patented
methods to measure TK1 protein levels, which provide valuable
information about the speed of cell turnover. A tumor has high cell
turnover (speed of cell division and cell death) and as a result TK1 can
be detected in the blood with a simple laboratory test, called TK 210
ELISA. The test provides valuable clinical information for prognosis and
optimization of treatment strategy. The test may also be used for
monitoring disease relapse. For more information, please see
This information is information that AroCell is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was
submitted for publication, through Jan Stålemark, at 11:45 CET on 6th October 2016. Redeye is AroCell:s Certified Adviser